65,437 trials
Pain
Primary: Number of Participants With Non-Painful Dressing Removal, Measured by Visual Aanalog Scale (VAS) — 44; 39 participants
Acute Oral Mucositis Pain
Primary: Mean Area Under the Curve (AUC) of Total Pain Reduction — 11.6; 11.7; 8.7 units on a scale*time scale — p=0.02
Fragile X-Associated Tremor/Ataxia Syndrome · Fragile X Premutation Carriers
Primary: Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II) — 17.44; 16.12; 15.66; 15.72 units on a scale
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…
Diffuse Large B Cell Lymphoma
Primary: Complete Response — 11 Participants
Blood Cancer · Advanced B Cell Malignancies
Primary: Number of Participants With Adverse Events — 3; 6; 4; 6 Participants
Atrial Fibrillation
Primary: Any First Post-op Atrial Fibrillation or Flutter (AF) — 233; 227 Participants
Prematurity
Primary: Number of Participants With Weight<10th Percentile for Age — 32; 41 Participants
Pain
Primary: Pain Score at 30 Minutes — 5.14; 5.05; 4.81 pain score
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Haemophilus Influenzae Type b · Acellular Pertussis · Diphtheria
Primary: Number of Subjects With Any Solicited Local Symptoms — 4; 2; 2; 0 Participants
Duration of Hospitalization
Primary: Hospital Length of Stay — 4.9; 4.4 Days — p=0.24
Hematopoietic/Lymphoid Cancer · Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants
Type 1 Diabetes Mellitus
Primary: Time Spent <70 mg/dL — 3.38; 3.44; 2.03; 3.27 hours per day — p=<0.0001
Schizophrenia · Schizoaffective Disorder · Major Depression
Primary: Plasma Levels of Triglycerides and Lipoprotein Cholesterol — 155; 182; 12.68; 16.92 mg/dL